. 2019 Aug 27;25:6436–6445. doi: 10.12659/MSM.916955

Table 4.

Percentage changes from baseline of function score in the included trials.

Study	Outcomes	Treatments	No. of patients	Baseline	% Change from baseline at different time points
Study	Outcomes	Treatments	No. of patients	Baseline	Day 7–14	Day 28–30	Final visit
Atchia 2011	WOMAC Function score	Durolane	19	6	NS	NS	NS
Atchia 2011	WOMAC Function score	Saline	19	6	NS	NS	NS
Brander 2018	WOMAC Function score	Hylan G-F 20	182	6.33±0.09	NA	−28.6%^***	−33.0%^***
Brander 2018	WOMAC Function score	Saline	175	6.44±0.08	NA	−28.4%^***	−33.1%^***
Migliore 2009	Lequesne index	Hyalubrix	22	7.09±3.78	NA	NA	−44.4%^**,^#
Migliore 2009	Lequesne index	Mepivacaine	20	7.75±4.15	NA	NA	−17.2%^**
Qvistgaard 2006	Lequesne index (1–24)	Hyalgan	33	10.0±4.0	NS	NS	NS
Qvistgaard 2006	Lequesne index (1–24)	Saline	36	9.5±3.8	NS	NS	NS
Richette 2009	WOMAC Function score	Adant	42	51.3±16.8	NA	NA	−13.1%
Richette 2009	WOMAC Function score	Saline	43	49.7±13.4	NA	NA	−11.5%

NS – not significant; WOMAC – Western Ontario and McMaster Universities Arthritis Index; NA – not available; VAS – visual analogue scale.

Achieved statistical significance (^* p<0.05; ^** p<0.01; ^*** p<0.001) compared to baseline;

achieved statistical significance (^# p<0.05; ^## p<0.01; ^### p<0.001) compared to placebo control.